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cute  or  Recurrent  Abdominal  Pain:  The Eyes Can Only
ee What  the  Mind  Knows!
or  Abdominal  Aguda  ou  Recorrente:  Só  Vemos  o  que  Conhecemos!
ngelo Zullo, Vincenzo Bruzzese, Cesare Hassan ∗arghe
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fnternal  Medicine  and  Gastroenterology  Unit,  ‘Nuovo  Regina  M
oth  angiotensin-converting  enzyme  inhibitors  (ACEIs)  and
ngiotensin  receptor  blockers  (ARBs)  are  largely  used  world-
ide  as  effective  treatment  of  blood  hypertension  and
ther  cardiovascular  diseases,  including  congestive  heart
ailure  and  diabetic  nephropathy.  For  instance,  in  2011  there
ere  164  million  prescriptions  of  ACEIs  and  86  million  pre-
criptions  of  ARBs  in  US.1 Generally,  these  drugs  are  well
olerated  and  safe.  However,  angioedema  has  been  reported
o  occur  in  0.1--0.7%  of  ACEIs/ARBs  users.2--4 This  drug-
nduced  condition  mainly  involves  the  head  and  neck  --  i.e.
he  facial  angioedema  --  with  swelling  of  the  face,  tongue,
nd  lips  which  occurs  in  about  one  of  2500  ACEIs  users.  An
solate  gastrointestinal  tract  involvement  --  i.e.  the  visceral
ngioedema  -- occurs  less  frequently.  Differently  from  the
acial  angioedema  that  suddenly  manifests  within  few  hours
r  days  from  the  start  of  therapy,  so  that  the  diagnosis  is
asily  suspected  at  clinical  history,  the  visceral  angioedema
iagnosis  may  remain  neglected  for  years.  Indeed,  visceral
ngioedema  no  rarely  presents  with  no  speciﬁc  acute  or
ecurrent  abdominal  symptoms,  mimicking  several  other
bdominal  diseases.  Therefore,  these  patients  may  undergo
epeated  investigations  and,  occasionally,  worthless  surgical
nterventions,  with  consequent  waste  of  health  resources
nd  morbidity  for  the  patient.
Since  ‘the  eyes  can  only  see  what  the  mind  knows’,
wareness  of  the  ACEIs/ARBs-induced  visceral  angioedema
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s  of  paramount  relevant  for  a  prompt  diagnosis  in  clinical
ractice.  A  systematic  review  described  27  cases  (82%
emales)  of  ACEIs-induced  visceral  angioedema  reported  in
iterature  until  2010.5 Of  note,  it  was  found  that  diagnosis
f  visceral  angioedema  was  performed  within  72  h  in  only
alf  of  the  cases,  whilst  in  46%  of  patients  it  was  delayed
etween  two  weeks  and  nine  years  of  ACEIs  therapy.  All
hese  patients  were  hospitalized  for  further  diagnostic
orkup,  and  some  of  them  also  underwent  unnecessary
bdominal  surgery  due  to  suspected  cholecystitis  or  appen-
icitis.  Clinical  presentation  always  includes  abdominal  pain
acute  or  recurrent)  with  or  without  vomiting,  ascites,  and
iarrhea.  In  addition,  a  relative  reduction  of  both  heart  rate
nd  blood  pressure  is  frequently  present.  Elevated  levels  of
radykinin  were  detected  in  all  cases  when  measured.  On
he  contrary,  mild  leukocytosis  appears  in  less  than  half  of
atients,  whilst  the  C1  esterase  inhibitor  and  complement
evels  are  normal.  At  CT  study,  diffuse  or  localized  thicken-
ng  of  small  bowel  is  present,  mainly  involving  the  jejunum,
leum  and  duodenum,  whilst  gastric,  oesophageal  and
olonic  localizations  are  infrequent.5,6 A  typical  CT  ﬁnding
s  the  so-called  ‘target  sign’  on  the  intestinal  wall,  with
ow-attenuation  of  the  submucosa  between  an  enhancing
ucosal  layer  and  an  outer  serosal  layer.7 Such  a  ﬁnding,
ogether  with  ascites  and  absence  of  other  radiological
igns  strongly  suggests  a  visceral  angioedema.  Indeed,  the
bsence  of  abdominal  masses,  lymphadenopathy,  stenosis,
stulas,  and  abscesses  allows  to  differentiate  such  diagnosis
rom  other  diseases,  including  inﬂammatory  bowel  diseases,
ymphoproliferative  diseases,  mesenteric  ischemia,  radia-
ion  enteritis,  Henoch-Schönlein  purpura,  and  eosinophilic
astroentroenteritis.7,8 A  complete  clinical  recovery
ccurs  within  24--48  h  of  drug  withdrawal.  Of  note,  the
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substitution  of  ACEI  with  an  ARB  is  not  always  safe,  given
that  angioedema  can  recur  in  up  to  one-third  of  patients,
at  least  for  the  facial  form.7
In  the  present  Journal,  visceral  angioedema  have  been
described  in  two  Portuguese  young  women  who  presented
at  Emergency  Department  for  acute  (<24  h)  abdominal  pain
that  occurred  two  days  and  15  days  following  ramipril  and
perindopril  therapy,  respectively.9,10 Typical  ‘target  sign’
on  intestinal  wall  and  ascites  were  detected  at  CT.  Both
patients  promptly  recovered  following  ACEI  therapy  with-
drawal.  This  further  demonstrates  that  when  the  condition  is
suspected  based  on  clinical  history  and  CT  ﬁndings,  the  diag-
nosis  can  be  safely  achieved  without  resorting  in  additional
and  useless  examinations.
In  conclusion,  a  patient  on  ACEI/ARB  therapy  presenting
with  acute  or  recurrent  abdominal  pain,  particularly  when
female,  should  be  suspected  with  visceral  angioedema,  and
the  clinician  should  alert  the  radiologist  to  look  for  ‘target
sign’  at  CT  study.
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